Your guess is as good as mine. The last licensing deal (Amgen) more than doubled our share price from around $7.50 to $16 before the subsequent dilution contributed to selling pressure back down. Now we are at $3 so a licensing deal I would think should take us up to at least $10, then if all goes well in the following year either Europe approval or a sale of the company takes us back to the low $20s.
News 
Market Data 
Discover 
AI
